These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 9266781

  • 21. Low-dose enalapril reduces angiotensin II and attenuates diabetic-induced cardiac and autonomic dysfunctions.
    Malfitano C, De Angelis K, Fernandes T, Wichi RB, Rosa K, Pazzine M, Mostarda C, Ronchi FA, Oliveira EM, Casarini DE, Irigoyen MC.
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):58-65. PubMed ID: 21921804
    [Abstract] [Full Text] [Related]

  • 22. Effects of enalapril on myocardial noradrenaline overflow during exercise in patients with chronic heart failure.
    Mulligan IP, Fraser AG, Lewis MJ, Henderson AH.
    Br Heart J; 1989 Jan; 61(1):23-8. PubMed ID: 2537095
    [Abstract] [Full Text] [Related]

  • 23. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.
    Jong P, Yusuf S, Rousseau MF, Ahn SA, Bangdiwala SI.
    Lancet; 2003 May 31; 361(9372):1843-8. PubMed ID: 12788569
    [Abstract] [Full Text] [Related]

  • 24. Contractile state is the major determinant of functional outcome in patients with left ventricular dysfunction treated with enalapril.
    Mirsky I, Aoyagi T, Ihara T, van Eyll C, Rousseau MF, Pouleur H.
    Eur Heart J; 1995 Jun 31; 16(6):808-17. PubMed ID: 7588925
    [Abstract] [Full Text] [Related]

  • 25. [Effect of angiotensin converting enzyme inhibitor lisinopril on sympathetic heart rate response during exercise in the early phase of acute myocardial infarction].
    Akashi Y, Tanabe K, Osada N, Samejima H, Seki A, Yokoyama Y, Nakayama M, Suzuki N, Oomiya K, Itoh H, Miyake F, Murayama M.
    J Cardiol; 2000 Oct 31; 36(4):221-9. PubMed ID: 11079227
    [Abstract] [Full Text] [Related]

  • 26. Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure.
    Blanchet M, Sheppard R, Racine N, Ducharme A, Curnier D, Tardif JC, Sirois P, Lamoureux MC, De Champlain J, White M.
    Am Heart J; 2005 May 31; 149(5):938.e1-7. PubMed ID: 15894946
    [Abstract] [Full Text] [Related]

  • 27. Reduction of exercise-induced myocardial ischemia during add-on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade.
    van den Heuvel AF, Dunselman PH, Kingma T, Verhorst P, Boomsma F, van Gilst WH, van Veldhuisen DJ.
    J Am Coll Cardiol; 2001 Feb 31; 37(2):470-4. PubMed ID: 11216965
    [Abstract] [Full Text] [Related]

  • 28. Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin.
    Vaynblat M, Shah HR, Bhaskaran D, Ramdev G, Davis WJ, Cunningham JN, Chiavarelli M.
    Eur J Heart Fail; 2002 Oct 31; 4(5):583-6. PubMed ID: 12413500
    [Abstract] [Full Text] [Related]

  • 29. Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction.
    Guazzi M, Melzi G, Marenzi GC, Agostoni P.
    Clin Pharmacol Ther; 1999 Mar 31; 65(3):319-27. PubMed ID: 10096264
    [Abstract] [Full Text] [Related]

  • 30. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy.
    Janbabai G, Nabati M, Faghihinia M, Azizi S, Borhani S, Yazdani J.
    Cardiovasc Toxicol; 2017 Apr 31; 17(2):130-139. PubMed ID: 27003392
    [Abstract] [Full Text] [Related]

  • 31. Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial.
    Dittrich S, Graf E, Trollmann R, Neudorf U, Schara U, Heilmann A, von der Hagen M, Stiller B, Kirschner J, Pozza RD, Müller-Felber W, Weiss K, von Au K, Khalil M, Motz R, Korenke C, Lange M, Wilichowski E, Pattathu J, Ebinger F, Wiechmann N, Schröder R, German Competence Network for Congenital Heart Defects and the Treat-NMD Neuromuscular Network Investigators list of additional local Investigators and co-workers of the German Competence Network for Congenital Heart Defects and the Treat-NMD Neuromuscular Network.
    Orphanet J Rare Dis; 2019 May 10; 14(1):105. PubMed ID: 31077250
    [Abstract] [Full Text] [Related]

  • 32. Ventricular unloading and improvement in left ventricular function after angiotensin converting enzyme inhibition with enalapril in patients with chronic congestive heart failure.
    Naganuma F, Kubota S, Hirahara N, Imai K, Kamiyama H, Iizuka T, Imai S, Murata K, Suzuki T.
    Jpn Circ J; 1994 Jan 10; 58(1):34-42. PubMed ID: 8139090
    [Abstract] [Full Text] [Related]

  • 33. Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state.
    Cleland JG, Dargie HJ, Ball SG, Gillen G, Hodsman GP, Morton JJ, East BW, Robertson I, Ford I, Robertson JI.
    Br Heart J; 1985 Sep 10; 54(3):305-12. PubMed ID: 2994698
    [Abstract] [Full Text] [Related]

  • 34. Intracoronary blockade of angiotensin-converting enzyme in humans: interaction with cardiac sympathetic neurotransmission?
    Rundqvist B, Eisenhofer G, Emanuelsson H, Albertsson P, Friberg P.
    Acta Physiol Scand; 1997 Sep 10; 161(1):15-22. PubMed ID: 9381945
    [Abstract] [Full Text] [Related]

  • 35. Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure.
    Jorde UP, Vittorio TJ, Dimayuga CA, Homma S, Rizkala A, Le Jemtel TH, Katz SD.
    Am J Cardiol; 2004 Dec 15; 94(12):1501-5. PubMed ID: 15589004
    [Abstract] [Full Text] [Related]

  • 36. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.
    McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J.
    Circulation; 1999 Sep 07; 100(10):1056-64. PubMed ID: 10477530
    [Abstract] [Full Text] [Related]

  • 37. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial.
    Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, Greenberg B, Klibaner MI, Kukin ML, Sugg JE, REVERT Study Group.
    Circulation; 2007 Jul 03; 116(1):49-56. PubMed ID: 17576868
    [Abstract] [Full Text] [Related]

  • 38. Long-term effects on cardiac output and peripheral resistance in patients treated with enalapril after acute myocardial infarction. CONSENSUS II Multi-Echo Study Group. Cooperative New Scandinavian Enalapril Survival Study.
    Edner M, Caidahl K, Bonarjee VV, Nilsen DW, Carstensen S, Berning J.
    Cardiology; 1998 May 03; 89(4):291-6. PubMed ID: 9643277
    [Abstract] [Full Text] [Related]

  • 39. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.
    Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM.
    Circulation; 2006 Dec 05; 114(23):2474-81. PubMed ID: 17101852
    [Abstract] [Full Text] [Related]

  • 40. Captopril or nifedipine? Comparison of rest and exercise acute effects and long-term therapy in chronic isolated asymptomatic moderate to severe aortic regurgitation.
    Banaszewski M, Rydlewska-Sadowska W, Rubkiewicz S.
    J Heart Valve Dis; 1998 Sep 05; 7(5):488-99. PubMed ID: 9793844
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.